BioPharma Resources

Therapeutic area

Infectious disease and vaccines

HIV, hepatitis, antibiotics, antifungals, antivirals and RSV. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

33

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

88

Industry-sponsored

Recruiting Phase 3

66

Industry-sponsored

Recruiting Phase 4 (post-approval)

11

Industry-sponsored

Recent approvals

All
  • Hibsago (Bepirovirsen Sodium) · Glaxosmithkline NovelPriority reviewOct 20, 2026

    To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

  • Hovilpri (Pritelivir Mesylate) · Aicuris Anti-Infect NovelPriority reviewOct 9, 2026

    To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

  • Utebzi (Tebipenem Pivoxil Hydrobromide) · Glaxosmithkline NovelPriority reviewJun 17, 2026

    To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

  • Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AG NovelPriority reviewMay 29, 2026

    To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

  • Xocova (Ensitrelvir) · Shionogi NovelMay 29, 2026

    To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 22, 2026

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Idvynso (Doravirine, Islatravir) · Msd NovelApr 20, 2026

    To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

  • Favlyxa (Fluorouracil) · Avyxa Holdings Feb 20, 2026
  • Nuzolvence (Zoliflodacin) · Entasis Therap NovelPriority reviewDec 12, 2025

    To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae

  • Clotic (Clotrimazole) · Carwin Pharm Assoc Priority reviewOrphanSep 26, 2025
  • Inlexzo (Gemcitabine Hydrochloride) · Janssen Biotech Breakthrough therapyPriority reviewSep 9, 2025
  • Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2025
  • Mavyret (Glecaprevir, Pibrentasvir) · Abbvie Breakthrough therapyPriority reviewOrphanJun 10, 2025
  • Enflonsia (Clesrovimab-Cfor) · Merck Sharp Dohme NovelPriority reviewJun 9, 2025

    To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • PovorcitinibINCB054707, INCB54707Phase 312 trials

    Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • CHO Cellrecombinant zoster vaccine, Recombinant Respiratory Syncytial Virus VaccinePhase 39 trials

    MAXVAX Biotechnology Limited Liability Company · Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ)

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • ElebsiranVIR-2218, BRII-835Phase 38 trials

    Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection

  • IBI362Phase 38 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea

  • RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials

    Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult

  • EfimosferminBOS-580Phase 37 trials

    GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic

  • Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster

  • PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease

  • TozorakimabMEDI3506Phase 36 trials

    AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure

  • HydronidoneF351Phase 35 trials

    Beijing Continent Pharmaceutical Co, Ltd. · Liver Fibrosis, Chronic Hepatitis B With Hepatic Fibrosis, Liver Fibrosis in Chronic Hepatitis B

  • RaphaminMMH-407Phase 35 trials

    Materia Medica Holding · Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic

  • rHuPH20Phase 35 trials

    Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma

Largest recruiting Phase 3 trials

All

More: Infectious disease and vaccines news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.